Speaker Profile
M.D., Ph.D., Chief Medical Officer, Encoded Tx
Biography
Sal Rico is a biotech executive and clinical pharmacologist with broad experience in patientcentered clinical development, covering small molecules, biologics, and medical devices. His expertise is particularly focused on orphan diseases and gene therapy. Before joining Encoded Therapeutics, he was Senior Vice President of Clinical Development at Audentes Therapeutics (now Astellas Gene Therapies). There, he managed the clinical development of AT132, an AAVbased gene therapy for Xlinked myotubular myopathy. He has designed, conducted, and analyzed Phase 14 clinical trials across various therapeutic areas and has played a significant role in garnering regulatory approval for several drugs, biological products, and medical devices such as INTERCEPT Blood System, Intermezzo, Hibor, and others.Prior to Audentes, he led clinical development teams at Cerus Corporation and TransceptPharmaceuticals. Additionally, he was as an investigator at the Centre for Drug Research, Hospital de la Santa Creu i Sant Pau in Barcelona, Spain.
Session Abstract – PMWC 2024 Silicon Valley
Track Co-Chairs:
Yael Weiss, Mahzi Tx
Peter Marks, FDA
- PMWC 2024 CGT Award Ceremony
Pioneer Honoree: Katherine A. High, AskBio
Pioneer Honoree: Timothy Yu, Boston Children's Hospital
- Piloting Interventional Genomics for Orphan Diseases
Keynote: Timothy Yu, Boston Children's Hospital
- Accelerated Approval for Small Populations: Biomarkers & Endpoints (PANEL)
Chair: Peter Marks, FDA
- Jennifer Puck, UCSF
- Katherine A. High, Rockefeller University
- Timothy Yu, Boston Children's Hospital - Novel Clinical Design Approaches in Rare Diseases (PANEL)
Chair: Adam Shaywitz, Bridge Bio
- Salvador Rico, Encoded Therapeutics
- Eric Crombez, Ultragenyx
- Elizabeth Berri Kravis, Rush University
- Empowering Patient Advocacy in Rare Disease Therapies (PANEL)
Chair: Yael Weiss, Mahzi Tx
- Charlene Son Rigby, STXBP1 Foundation
- Michael Graglia, Syngap Research Fund - Advancing the Frontier: Gene and Cell Therapies for Rare Diseases (PANEL)
Chair: Matthew Porteus, Stanford
- Swati Tole, Capsida Biotherapeutics
- Adrian Veres, Dyno Therapeutics
- Thomas Wechsler, J&J
- David Lebwohl, Intellia Therapeutics
- Pooja Agarwal, BioMarin Pharmaceutical
